Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Direkt zur Navigaton springen.
Direkt zum Inhalt springen.

Navigation/Suche

Gewählte Publikation:

FRIDRIK, MA; FELBERMAYR, M; LINKESCH, W; NEUBAUER, M; SCHILLER, L; HAUSMANINGER, H; OPPITZ, P; GATTRINGER, C.
2-CHLORODESOXYADENOSINE - FIRST-LINE TREATMENT FOR LOW-GRADE NON-HODGKINS-LYMPHOMAS - A PHASE-II/III STUDY OF THE ARBEITSGEMEINSCHAFT-MEDIKAMENTOSE-TUMORTHERAPIE
ONKOLOGIE. 1995; 18(1): 39-43. Doi: 10.1159/000218552
Web of Science FullText FullText_MUG

Co-Autor*innen der Med Uni Graz: Linkesch Werner
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: Background: Treatment of advanced low-grade non-Hodgkin's lymphoma (NHL) remains palliative. For a good palliation a high remission rate with low toxicity is required. 2-Chlorodesoxyadenosine (2-CdA) is a new purine analog with a toxic effect to resting and proliferating lymphocytes. Phase II studies of 2-CdA in pretreated patients with low-grade NHL showed promising results. Interferon can prolong chemotherapy-induced remissions. Material and Methods: Endpoints of this trial are response, survival, time to treatment failure, time to relapse, and toxicity of Z-CdA induction and interferon-alpha-2c (IF) maintenance as first-line treatment in low-grade NHL. 2-CdA, 0.12 mg/kg body weight in 500 ml NaCl 0.9%, is given as a 2-hour infusion five times daily. Four cycles are given in responding patients in 4-week intervals. After the 2-CdA induction treatment, responding patients are put on maintenance treatment with interferon-alpha-2c, 15 mu g subcutaneously 3 times weekly for 1 year. Results: Up to September 1, 1994, 13 patients were entered, median age 52 years (range 35-74 years). All patients had stage IV disease. Ten patients had centroblastic-centrocytic histology, 3 had Waldenstrom macroglobulinemia. Six patients have finished their 2-CdA treatment. All patients had a remission, 4 had complete remission (CR). After a median observation time of 7 months we observed 2 relapses. One patient died of lymphoma. One patient had a granulocyte nadir below 1.0x10(9)/I, 2 had platelet counts below 100x10(9)/I. Four patients had infections, one of WHO grade 3. No other toxicities were observed. Conclusion: These results are encouraging; the study is open until 50 patients will have been entered.
Find related publications in this database (Keywords): NON-HODGKINS LYMPHOMA; LOW-GRADE; TREATMENT OF NHL; 2-CDA; INTERFERON